MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Search

AtriCure Inc

Atvērts

SektorsVeselības aprūpe

39.48 1.05

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

38.3

Max

39.59

Galvenie mērījumi

By Trading Economics

Ienākumi

5.9M

-267K

Pārdošana

-1.9M

134M

Peļņas marža

-0.199

Darbinieki

1,300

EBITDA

7.3M

8M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+34.9% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 11. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

76M

1.9B

Iepriekšējā atvēršanas cena

38.43

Iepriekšējā slēgšanas cena

39.48

Ziņu noskaņojums

By Acuity

60%

40%

315 / 360 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

AtriCure Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. janv. 23:49 UTC

Galvenie tirgus virzītāji

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

2026. g. 21. janv. 21:12 UTC

Galvenie tirgus virzītāji

Automaker Stocks Rise After Trump Calls Off European Tariffs

2026. g. 21. janv. 21:00 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

2026. g. 21. janv. 20:29 UTC

Galvenie tirgus virzītāji

Chip Makers Gain After Trump Calls Off European Tariffs

2026. g. 21. janv. 20:04 UTC

Galvenie tirgus virzītāji

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

2026. g. 21. janv. 23:48 UTC

Tirgus saruna

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

2026. g. 21. janv. 23:34 UTC

Tirgus saruna

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

2026. g. 21. janv. 22:39 UTC

Peļņas

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

2026. g. 21. janv. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 21. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 21. janv. 21:35 UTC

Iegādes, apvienošanās, pārņemšana

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

2026. g. 21. janv. 21:19 UTC

Peļņas

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

2026. g. 21. janv. 20:45 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Borse Group to Acquire Allfunds for $6.19B

2026. g. 21. janv. 20:36 UTC

Tirgus saruna

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

2026. g. 21. janv. 20:31 UTC

Tirgus saruna

Oil Settles Higher With Support From Heating Fuel -- Market Talk

2026. g. 21. janv. 20:27 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

2026. g. 21. janv. 20:27 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 21. janv. 20:27 UTC

Tirgus saruna

Was It a 'TACO' Event? -- Market Talk

2026. g. 21. janv. 20:26 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

2026. g. 21. janv. 20:23 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

2026. g. 21. janv. 20:21 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

2026. g. 21. janv. 20:19 UTC

Iegādes, apvienošanās, pārņemšana

Deutsche Boerse Group Agrees to Buy Allfunds

2026. g. 21. janv. 20:08 UTC

Peļņas

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

2026. g. 21. janv. 20:03 UTC

Tirgus saruna

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

2026. g. 21. janv. 19:51 UTC

Tirgus saruna

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

2026. g. 21. janv. 19:43 UTC

Tirgus saruna

U.S. Ethanol Production Expected to Slip -- Market Talk

2026. g. 21. janv. 19:31 UTC

Tirgus saruna

Gold Settles at Fresh All-Time High -- Market Talk

2026. g. 21. janv. 19:24 UTC

Peļņas

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

2026. g. 21. janv. 19:10 UTC

Tirgus saruna

Mexican Inflation Seen Picking Up in Early January -- Market Talk

2026. g. 21. janv. 18:57 UTC

Tirgus saruna

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Salīdzinājums

Cenas izmaiņa

AtriCure Inc Prognoze

Cenas mērķis

By TipRanks

34.9% augšup

Prognoze 12 mēnešiem

Vidējais 51.83 USD  34.9%

Augstākais 64 USD

Zemākais 45 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AtriCure Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

6

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

30.36 / 33.4Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

315 / 360 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par AtriCure Inc

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
help-icon Live chat